Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept plus docetaxel/prednisone vs placebo plus docetaxel/prednisone in metastatic androgen-independent (castration-resistant) prostate cancer
2006-004756-20Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Aflibercept + docetaxel/prednisone or prednisolone with Placebo + docetaxel/prednisone or prednisolone (2 arms). Primary endpoint: Overall survival. Started Jun 2007; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2006-004756-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004756-20.